Hansa Medical in brief

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage clinical development for kidney transplant patients, with the potential for further development in other solid organ transplantation and acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects, including NiceR, through which the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on NASDAQ Stockholm (HMED).

Key facts

  • Innovative and promising pipeline
    • Imlifidase – candidate drug in several Phase 2 trials in kidney transplantation
    • NiceR - Novel immunoglobulin cleaving enzymes for Repeat dosing
    • EnzE - Enzyme based antibody Enhancement
    • HBP-assay – diagnostic assay to predict severe sepsis (licensed to Axis-Shield Diagnostics)
  • First-rate global scientific network within transplantation and immunology
  • Board of Directors with long pharma and biotech experience
  • Small and innovative team (Approx. 50 employees)
  • Based in Lund, Sweden
  • Listed on NASDAQ Stockholm (ticker: HMED)
  • 483 MSEK in cash and short term investments, November 30, 2018